350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC

Granahan Investment Management LLC purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the third quarter, according to its most recent disclosure with the SEC. The firm purchased 350,168 shares of the company’s stock, valued at approximately $2,850,000. Granahan Investment Management LLC owned approximately 0.21% of Xeris Biopharma at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. AlphaQuest LLC acquired a new position in shares of Xeris Biopharma during the third quarter valued at approximately $35,000. State of Alaska Department of Revenue acquired a new stake in shares of Xeris Biopharma in the third quarter worth approximately $68,000. Tower Research Capital LLC TRC increased its position in shares of Xeris Biopharma by 913.1% during the second quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock worth $81,000 after purchasing an additional 15,678 shares in the last quarter. Modern Wealth Management LLC purchased a new stake in shares of Xeris Biopharma during the second quarter worth approximately $83,000. Finally, Los Angeles Capital Management LLC acquired a new position in Xeris Biopharma in the 2nd quarter valued at $95,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XERS. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd. Barclays began coverage on Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Xeris Biopharma has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $7.43, for a total transaction of $123,835.81. Following the completion of the transaction, the insider directly owned 1,308,103 shares in the company, valued at $9,719,205.29. This trade represents a 1.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Johnson sold 135,400 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the sale, the director owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 225,308 shares of company stock worth $1,626,103 in the last 90 days. Insiders own 4.56% of the company’s stock.

Xeris Biopharma Stock Up 0.5%

Xeris Biopharma stock opened at $5.49 on Tuesday. The company has a market capitalization of $946.64 million, a PE ratio of -548.45 and a beta of 0.61. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $10.08. The firm has a 50 day moving average price of $6.87 and a 200 day moving average price of $7.49.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.